| HOME >> BIOLOGY >> TECHNOLOGY |
LEXINGTON, Mass., June 2 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Roch W. Kelly as Chief Operating Officer, effective immediately.
"As RainDance solutions enter commercial development, Mr. Kelly is the ideal leader to establish our manufacturing and financial capabilities," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "With more than 20 years of experience in life sciences, he brings a proven record of successfully implementing the process and controls in these critical areas to meet the anticipated demand for our products."
Kelly joins RainDance from Synarc, Inc., where he was Vice President, Clinical Operations. Under his leadership, the operational team rapidly implemented new processes and systems that achieved a 25% improvement in efficiency. Previous positions included Chief Operating Officer and Chief Financial Officer at Protedyne, Inc., and Vice President, Clinical Operations and Worldwide Business, at PAREXEL International. He also served as Executive Director of Manufacturing Operations at Chiron Diagnostics. Kelly received a Bachelor of Science degree in finance from Miami (Ohio) University and a Master of Business Administration degree from Syracuse University.
About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.
The company's technology produces picoliter-sized droplets at a rate of
10 million per hour. Each droplet is the functional equivalent of an
individual test tube and can contain a single molecule, reaction, or cell.
This versatile technology can adapt highly referenced assay
'/>"/>
| SOURCE RainDance Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |